ULTRAGENYX PHARMACEUTICAL INC. Deferred Tax Liabilities, Gross
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Deferred Tax Liabilities, Gross of $35.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-18
- 2025-12-31: Deferred Tax Liabilities, Gross $35.00M.
- 2024-12-31: Deferred Tax Liabilities, Gross $36.00M; Deferred Tax Liabilities, Gross as first filed $35.84M.
- 2023-12-31: Deferred Tax Liabilities, Gross $36.02M.
- 2022-12-31: Deferred Tax Liabilities, Gross $37.81M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $35.00M 10-K · filed 2026-02-18 | |
| 2024-12-31 | $36.00M 10-K · filed 2026-02-18 | $35.84M 10-K · filed 2025-02-19 |
| 2023-12-31 | $36.02M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $37.81M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $42.25M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $66.65M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $40.97M 10-K · filed 2021-02-12 | |
| 2018-12-31 | $31.17M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |